Cargando…
The Use of Cognitive Screening in Pharmacotherapy Trials for Cognitive Impairment Associated With Schizophrenia
There are currently no regulatory approved pharmacological treatments for cognitive impairment associated with schizophrenia (CIAS). One possibility is that trial methodology itself is hindering their development. Emerging evidence suggests that patients with schizophrenia may show limited benefit f...
Autores principales: | Cotter, Jack, Barnett, Jennifer H., Granger, Kiri |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743013/ https://www.ncbi.nlm.nih.gov/pubmed/31551837 http://dx.doi.org/10.3389/fpsyt.2019.00648 |
Ejemplares similares
-
F74. CLINICAL SYMPTOMS AND NOT OBJECTIVE COGNITIVE PERFORMANCE DRIVE SUBJECTIVE COGNITIVE COMPLAINTS IN PATIENTS WITH SCHIZOPHRENIA
por: Cotter, Jack, et al.
Publicado: (2018) -
S74. EXPLORING PARTICIPANT-LEVEL TRAJECTORIES OF COGNITIVE PERFORMANCE AMONG PATIENTS WITH SCHIZOPHRENIA IN A MULTI-NATIONAL TRIAL
por: Granger, Kiri, et al.
Publicado: (2018) -
Using Affective Cognition to Enhance Precision Psychiatry
por: Cotter, Jack, et al.
Publicado: (2018) -
T79. AFFECTIVE FACE PROCESSING IN SCHIZOPHRENIA: DISORDER-SPECIFIC OR TRANSDIAGNOSTIC DEFICIT?
por: Cotter, Jack, et al.
Publicado: (2018) -
Association of Cognitive Impairment With Anhedonia in Patients With Schizophrenia
por: Yu, Lingfang, et al.
Publicado: (2021)